Fungal Infections in Non-neutropenic Patients

A special issue of Journal of Fungi (ISSN 2309-608X). This special issue belongs to the section "Fungal Pathogenesis and Disease Control".

Deadline for manuscript submissions: 31 January 2025 | Viewed by 2552

Special Issue Editors


E-Mail Website
Guest Editor
First Department of Critical Care Medicine and Pulmonary Services, Evangelismos Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
Interests: nosocomial infections; invasive fungal disease; aspergillosis; antifungal/antimicrobial stewardship; COVID-19
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Intensive Care Unit, Evaggelismos Hospital, National and Kapodistrian University of Athens, 15772 Athens, Greece
Interests: infection; fungi; resistance; intensive care medicine; systemic mycosis; invasive fungal infection; candidiasis; antifungal treatment regimens

Special Issue Information

Dear Colleagues,

The increasing incidence of systemic fungal infections in general wards and in critical care units is directly related to the growing number of immunocompromised individuals due to aging, cancer chemotherapies, autoimmune disorders typically treated with immunosuppressive drugs, critical illnesses, and other aspects, resulting in superficial, deep, and systemic mycoses. Aspergillosis, Mucormycosis, Candidiasis, Cryptococcosis, fungal neglected tropical diseases (chromoblastomycosis, paracoccidioidomycosis), and AIDS-related mycoses account for superficial, deep, and systemic mycoses, while Candida auris is considered a serious global health threat. Additionally, the emergence of triazole and echinocandin resistance complicated the selection of an appropriate antifungal treatment. Fungal dose optimization is closely related to successful therapeutic management that might overcome certain types of antifungal resistance. Therefore, the establishment of antifungal stewardship programs, especially in immunocompromized non-neutropenic patients in any clinical setting, is of the utmost importance.

The aim of this Special Issue is to cover multiple aspects of fungal dose optimization, risk factors for systemic mycoses, epidemiological aspects, and several fungus-related clinical challenges. Authors with research interests and expertise in this topic are invited to contribute in order to enhance the knowledge in this area and improve its clinical management.

Dr. Eleni Magira
Dr. Olga Kampouropoulou
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Fungi is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • epidemiology
  • systemic emerging mycoses
  • antifungal resistance
  • antifungal stewardship

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 2788 KiB  
Article
Candida Non-albicans and Non-auris Causing Invasive Candidiasis in a Fourth-Level Hospital in Colombia: Epidemiology, Antifungal Susceptibility, and Genetic Diversity
by Juan Camilo Hernández-Pabón, Bryan Tabares, Óscar Gil, Carlos Lugo-Sánchez, Aldair Santana, Alfonso Barón and Carolina Firacative
J. Fungi 2024, 10(5), 326; https://doi.org/10.3390/jof10050326 - 30 Apr 2024
Cited by 3 | Viewed by 2002
Abstract
Increasingly common and associated with healthcare settings, Candida infections are very important, since some species of this genus can develop antifungal resistance. We contribute data on the epidemiology, antifungal susceptibility, and genetic diversity of Candida non-albicans and non-auris affecting critically ill [...] Read more.
Increasingly common and associated with healthcare settings, Candida infections are very important, since some species of this genus can develop antifungal resistance. We contribute data on the epidemiology, antifungal susceptibility, and genetic diversity of Candida non-albicans and non-auris affecting critically ill patients in a fourth-level hospital in Colombia. Ninety-seven isolates causing invasive infections, identified by conventional methods over 18 months, were studied. Data from patients affected by these yeasts, including sex, age, comorbidities, treatment, and outcome, were analysed. The antifungal susceptibility of the isolates was determined, and the ribosomal DNA was sequenced. Candida parapsilosis, Candida tropicalis, Candida glabrata, Candida dubliniensis, and Candida guilliermondii caused 48.5% of all cases of invasive candidiasis. The species were mainly recovered from blood (50%). Patients were mostly men (53.4%), between 18 days and 93 years old, hospitalized in the ICU (70.7%). Overall mortality was 46.6%, but patients in the ICU, using antibiotics, with diabetes mellitus, or with C. glabrata infections were more likely to die. Resistant isolates were identified in C. parapsilosis, C. tropicalis, and C. glabrata. This study provides epidemiological data for the surveillance of emerging Candida species, highlighting their clinical impact, as well as the emergence of antifungal resistance and clonal dispersal. Full article
(This article belongs to the Special Issue Fungal Infections in Non-neutropenic Patients)
Show Figures

Figure 1

Back to TopTop